CICC reported that ZAI LAB's revenue decreased by 6% year-over-year, resulting in a net loss of USD51 million, which was in line with expectations. The firm highlighted ongoing clinical trials for Zoci and other potential blockbuster candidates, advising investors to focus on upcoming data readouts. However, due to competitive pricing pressures, CICC revised its earnings forecasts for 2026 and 2027, leading to an 8% reduction in target prices while maintaining an Outperform rating.
